Journal of Inherited Metabolic Disease

, Volume 31, Issue 2, pp 173–177

The consequences of extended newborn screening programmes: Do we know who needs treatment?

SSIEM Symposium 2007

DOI: 10.1007/s10545-008-0843-8

Cite this article as:
Wilcken, B. J Inherit Metab Dis (2008) 31: 173. doi:10.1007/s10545-008-0843-8
  • 131 Views

Summary

The development of an evidence base for newborn screening is especially difficult because of the rarity of disorders now detectable. One consequence of expanded newborn screening is that physicians are being called upon to manage asymptomatic babies with persistent biochemical disturbances that indicate likely enzyme deficiencies. Some of these may be very mild. There is not always agreement as to who should be treated. Particular problems are seen with disorders that were previously thought very rare but are now found frequently by newborn screening. Some of these disorders appear benign or nearly so, and in the present state of knowledge should clearly not be included in routine newborn screening panels.

Abbreviations

MCAD

medium-chain acyl-CoA dehydrogenase

3MCCC

3-methylcrotonyl-CoA carboxylase

PKU

phenylketonuria

Copyright information

© Springer Science+Business Media B.V. 2008

Authors and Affiliations

  1. 1.Biochemical Genetics and Newborn ScreeningThe Children’s Hospital at WestmeadWestmeadAustralia
  2. 2.The University of SydneySydneyAustralia